CytomX Therapeutics CTMX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $12.67M-66.7% | $38.05M+122% | $17.17M-91.1% | $193.65M-5.8% | ||
| $124.39M+98.8% | $62.57M-60.2% | $157.34M— | $0-100% | ||
| $2.01M-35.1% | $3.1M-9.6% | $3.43M-90.5% | $35.99M+4,455% | ||
| $143.92M+34.1% | $107.31M-41.3% | $182.94M-22.8% | $237.1M-23.6% | ||
| $1.3M-47.1% | $2.47M-37.7% | $3.96M-22.0% | $5.07M-14.9% | ||
| $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | ||
| $438K-24.9% | $583K-20.0% | $729K-16.7% | $875K-14.3% | ||
| $151.57M+25.7% | $120.53M-40.3% | $201.79M-22.7% | $260.89M-23.1% | ||
| $1.3M+19.6% | $1.09M-25.4% | $1.46M-48.1% | $2.81M-0.3% | ||
| $26.88M-60.0% | $67.2M-49.2% | $132.27M+9.1% | $121.27M+197% | ||
| $46.62M-45.7% | $85.77M-45.0% | $155.91M+2.2% | $152.61M+96.0% | ||
| $52.56M-56.6% | $120.99M-51.5% | $249.24M-28.1% | $346.64M+2.0% | ||
| $2K+100% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$711.95M-2.9% | -$691.58M+4.4% | -$723.45M-0.1% | -$722.88M-15.9% | ||
| $99.01M+21,812% | -$456K+99.0% | -$47.45M+44.7% | -$85.75M-18,582% | ||
| $151.57M+25.7% | $120.53M-40.3% | $201.79M-22.7% | $260.89M-23.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CytomX Therapeutics's total assets?
- CytomX Therapeutics (CTMX) holds $359.4M in total assets, up 264.8% year over year.
- How much debt does CytomX Therapeutics have?
- CytomX Therapeutics carries $2.9M in total debt against $319.9M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does CytomX Therapeutics have?
- CytomX Therapeutics holds $28.8M in cash and equivalents.
- Can CytomX Therapeutics cover its short-term obligations?
- Its current ratio is 10.38 — current assets exceed current liabilities.
- Where does CytomX Therapeutics's balance sheet data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
